Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adial Pharmaceuticals Inc.

www.adialpharma.com

Latest From Adial Pharmaceuticals Inc.

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies

IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First

Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • ADial Pharmaceuticals LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Adial Pharmaceuticals Inc.
  • Senior Management
  • William B Stilley, CEO
    Joseph Truluck, COO & CFO
    Zastawny H Tomasz , PhD, Chief Dev. Officer
  • Contact Info
  • Adial Pharmaceuticals Inc.
    Phone: (434) 422-9800
    1180 Seminole Trail
    Suite 495
    Charlottesville, VA 22901
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register